Astellas Mid-Term Plan FY18-FY20e: Concerns Remain Over Growth Post-Xtandi LOE
Astellas Pharma Inc (4503 JP) announced it FY18-20e mid-term plan on May 22, 2018 While our FY20e sales estimates are in-line with the company...
150 Views
Astellas FY17 Results and FY18e Guidance – No Major Surprise
Astellas Pharma Inc (4503 JP) FY17 results Xtandi (up 17% to ¥295b) and mirabegron (up 28% to ¥126b) ramp-up compensate for lackluster domestic...
112 Views
Japan Pharma - FY17e Earnings Preview (I)
Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...
91 Views
Global Equity Strategy: Opportunities in Japan, HK, & EM
In our April International Strategy, we explore the recent consolidation across global equity markets and examine the following opportunities...
184 Views
Japan Pharmaceutical - Sector Overview
Core coverage – relative valuations Takeda Pharmaceutical Co Ltd (4502 JP) (NB: Pre-Shire announcement | Pro-Forma analysis to be published...
135 Views